Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) had its target price decreased by equities researchers at Piper Sandler to $2.00 in a report issued on Monday, Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Sandler‘s target price indicates a potential upside of 399.50% from the company’s previous close.
Several other equities research analysts also recently commented on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Akebia Therapeutics in a research note on Thursday, August 6th. BTIG Research reiterated a “buy” rating and issued a $4.00 target price on shares of Akebia Therapeutics in a report on Tuesday, September 15th. Wall Street Zen cut shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, November 9th. Westpark Capital started coverage on shares of Akebia Therapeutics in a research report on Tuesday, September 8th. They set a “buy” rating and a $4.50 price target on the stock. Finally, Leerink Partners lowered shares of Akebia Therapeutics from an “outperform” rating to a “market perform” rating and set a $1.00 price target for the company. in a report on Friday, August 7th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $3.50.
Get Our Latest Stock Analysis on AKBA
Akebia Therapeutics Stock Down 10.7%
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.04). Akebia Therapeutics had a negative net margin of 22.60% and a negative return on equity of 156.59%. The business had revenue of $36.90 million for the quarter, compared to the consensus estimate of $46.94 million. Analysts anticipate that Akebia Therapeutics will post -0.17 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Akebia Therapeutics
Institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in Akebia Therapeutics during the third quarter worth $37,000. Goldman Sachs Group Inc. grew its position in Akebia Therapeutics by 19.9% in the third quarter. Goldman Sachs Group Inc. now owns 4,423,717 shares of the biopharmaceutical company’s stock valued at $4,070,000 after purchasing an additional 734,550 shares in the last quarter. Ieq Capital LLC increased its stake in Akebia Therapeutics by 59.7% in the 3rd quarter. Ieq Capital LLC now owns 147,574 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 55,195 shares during the last quarter. Virtus Advisers LLC increased its stake in Akebia Therapeutics by 16.1% in the 3rd quarter. Virtus Advisers LLC now owns 366,672 shares of the biopharmaceutical company’s stock valued at $337,000 after buying an additional 50,935 shares during the last quarter. Finally, Alps Advisors Inc. lifted its position in Akebia Therapeutics by 33.7% during the 3rd quarter. Alps Advisors Inc. now owns 364,094 shares of the biopharmaceutical company’s stock worth $335,000 after buying an additional 91,832 shares in the last quarter. Institutional investors own 33.92% of the company’s stock.
About Akebia Therapeutics
Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for people affected by kidney disease. Founded in 2007 and based in Cambridge, Massachusetts, the company’s work has centered on anemia and other complications associated with chronic kidney disease. Its products include Vafseo (vadadustat), an oral treatment for anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, and Auryxia (ferric citrate).
Further Reading
- Five stocks we like better than Akebia Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
